Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic evaluation of long-term Xolair therapy in severe allergic asthma
NL-OMON25198Recruiting
- Sponsor
- Frisius MC
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of omalizumab in allergic asthma and asthma, sponsored by Frisius MC. Started Jun 2019; status: recruiting.
02
Drugs
omalizumab
03
Conditions
allergic asthmaasthma
Beyond the preview
Go deeper on NL-OMON25198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25198.